Company Filing History:
Years Active: 2022
Introduction
Malcolm Ngiam is a distinguished inventor based in Hong Kong, CN, known for his contributions to biomedical research. With a focus on recombinant human-basic fibroblast growth factor (rh-bFGF), he has made significant advances in pharmaceutical compositions that have the potential to impact therapeutic applications.
Latest Patents
Ngiam holds two notable patents that encapsulate his innovative work. The first patent, titled "Recombinant human-basic fibroblast growth factor (rh-bFGF) and pharmaceutical composition comprising rh-bFGF," introduces a mutated nucleic acid molecule of rh-bFGF, along with its pharmaceutical composition. This invention provides insights into the practical applications of rh-bFGF in the medical field.
His second patent, "Method for producing soluble recombinant human-basic fibroblast growth factor (rh-bFGF)," lays out a method for producing soluble rh-bFGF, which includes a mutated nucleic acid molecule that encodes this groundbreaking factor.
Career Highlights
Malcolm Ngiam currently works at Zhuhai Essex Bio-Pharmaceutical Co., Ltd., an organization where he continues to push the boundaries of biomedical innovation. His dedication to research and development has contributed to the progression of vital therapies that may significantly improve patient outcomes.
Collaborations
In his professional journey, Ngiam collaborates with esteemed colleagues, including Haizhou Fang and Peimin Dai. Their combined expertise enhances the scientific rigor of their research projects, fostering an environment of innovation and creative problem-solving.
Conclusion
Malcolm Ngiam's innovative approach to biomedical research is evident through his patents and collaborative efforts. His work in recombinant human-basic fibroblast growth factor has the potential to lead to significant advancements in medical treatments, showcasing the vital role of inventors like him in shaping the future of healthcare.